Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Bicycle Therapeutics Plc ADR shares valued at $157,114 were sold by Thompson Travis Alvin on Nov 11 ’24. At $25.11 per share, Thompson Travis Alvin sold 6,256 shares. The insider’s holdings dropped to 19,241 shares worth approximately $0.39 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Thompson Travis Alvin purchased 6,256 shares, netting a total of over 157,112 in proceeds.
Before that, Lee Kevin had sold 3,212 shares from its account. In a trade valued at $71,499, the CHIEF EXECUTIVE OFFICER traded Bicycle Therapeutics Plc ADR shares for $22.26 each. Upon closing the transaction, the insider’s holdings decreased to 3,212 shares, worth approximately $7.72 million.
As published in their initiating research note from Stephens on November 08, 2024, Bicycle Therapeutics Plc ADR [BCYC] has been an Equal-weight and the price target has been revised to $25. Analysts at RBC Capital Mkts started covering the stock with ‘”an Outperform”‘ outlook in a report released in early September. As of August 07, 2024, B. Riley Securities has decreased its “Buy” rating to a “Neutral” for BCYC. Earlier on September 11, 2023, B. Riley Securities upgraded its rating. Their new recommendation was “a Buy” for BCYC stock which previously was a “a Neutral”.
Analyzing BCYC Stock Performance
During the last five days, there has been a drop of approximately -10.27%. Over the course of the year, Bicycle Therapeutics Plc ADR shares have jumped approximately 12.06%. Shares of the company reached a 52-week high of $28.67 on 10/16/24 and a 52-week low of $16.13 on 01/05/24. A 50-day SMA is recorded $24.09, while a 200-day SMA reached $23.23. Nevertheless, trading volume fell to 0.85 million shares from 0.27 million shares the previous day.
Support And Resistance Levels for Bicycle Therapeutics Plc ADR (BCYC)
According to the 24-hour chart, there is a support level at 19.84, which, if violated, would cause prices to drop to 19.41. In the upper region, resistance lies at 20.70. The next price resistance is at 21.13. RSI (Relative Strength Index) is 27.95 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -2.29, which suggests the price will decrease in the coming days. Percent R is at 92.59%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
